Invicro Scientific Team
Invicro’s approach to research is built upon the expertise of our multidisciplinary team, which is made up of over 150 research scientists with backgrounds in a variety of disciplines. Our scientists have advanced degrees in medicine, optics, engineering (electrical, chemical, biomedical, software, mechanical, computer), mathematics, neuroscience, chemistry, molecular biology and statistics, among others.
Our solutions are provided through collaboration among smart people using innovation to solve difficult research problems. The application of the broad and deep knowledge of our team allows us to provide a specialized approach to solving the research problems of our sponsors. If you would like to learn about joining our team, please visit our Careers page.
Invicro was founded by a small group who recognized a need for a fully integrated portfolio of imaging solutions and with a shared goal of being a research partner for anyone needing imaging services or software. Since founding the company, Invicro’s leadership team has grown the company organically with a focus on providing innovation and solutions to drug discovery and development.
Dr. Hoppin is the Co-Founder and CEO of Invicro. Dr. Hoppin holds a Ph.D. in Applied Mathematics from the University of Arizona and worked as an Alexander von Humboldt post-doctoral fellow at the Research Center Jülich, Germany. Prior to co-founding Invicro in 2008, Dr. Hoppin served as the VP of Imaging Systems at Bioscan, Inc. He has been working in imaging research for more than 15 years. As an active member of the imaging community, Dr. Hoppin is a member of the World Molecular Imaging Society Board of Trustees.
Dr. Lackas is the Co-Founder and Managing Partner of Invicro. He is the architect of Invicro’s software platforms and manages the continued development of Invicro’s growing array of software solutions for imaging laboratories. Dr. Lackas holds a Ph.D. (Dr. rer. nat.) in High Energy Physics and a Master (Dipl.-Phys.) in Physics and Computer Science from RWTH Aachen University, Germany. He gathered extensive experience with large scale scientific data acquisition systems during his appointment at DESY, and during his position as Director, Image Application and Software Development at Bioscan, Inc. where he was instrumental for the NanoSPECT/CT project. At Invicro, Dr. Lackas’ prime objective is to provide software solutions according to highest scientific standards to enable and support researchers in their day-to-day operation with imaging.
Ms. Murgia is a founding member of Invicro and currently serves as its Chief Operating Officer. Since the company’s founding in 2008, Ms. Murgia has been responsible for organizational infrastructure and development. She oversees a variety of functional areas including finance and accounting, human resources, facilities, general administration and marketing. After beginning her career in nonprofit program and organizational management she transitioned into the corporate sector as cause marketing manager at Macy’s working on national awareness and multi-million dollar fundraising campaigns. Ms. Murgia’s academic degrees include a BA in Ethics from the College of the Holy Cross and an MBA with honors from the Universiteit Maastricht (Maastricht, The Netherlands). Her master’s work was focused on small business corporate social responsibility.
Dr. Seibyl is an international expert on PET and SPECT imaging for neurodegenerative disorders. He is past President of the Brain Imaging Council of the Society of Nuclear Medicine. Dr. Seibyl is dually-boarded in Nuclear Medicine and Psychiatry and has twenty years of experience in clinical studies. He has made significant contributions to development of visual and quantitative analysis for PET imaging in neurodegenerative and neuropsychiatric disorders. Along with Dr. Marek he has directed and continues to direct several international multicenter imaging studies. Dr. Seibyl is an author on over hundred publications on CNS imaging.
Dr. Marek is a neurologist with widespread expertise in neurodegenerative disorders. He is internationally recognized as an expert in imaging of neurodegenerative disorders and has made significant contributions to early detection and diagnostic use of radiotracers for these disorders for PD, AD, HD and other disorders. He has developed novel clinical design for brain imaging studies and has been the Principal Investigator in several multicenter trials including PPMI and PARS.
Dr. Hesterman is Invicro’s Executive VP of Image Analysis. The image analysis group focuses on the development of novel image processing methods and the engineering of robust, efficient image processing tools. These tools are used to extract the quantitative information required to support projects spanning multiple imaging modalities and therapeutic areas. Dr. Hesterman holds a Ph.D. from the University of Arizona’s College of Optical Sciences, having completed a research project in small-animal SPECT at the Center for Gamma Ray Imaging. Prior to joining Invicro, Dr. Hesterman managed Bioscan’s NanoSPECT/CT project for several years while living in Budapest, Hungary, and served as a visiting scientist in the Frangioni Lab at Beth Israel Deaconess Medical Center, a Harvard Medical School Teaching Hospital.
Dr. Tamagnan received his PhD in Medicinal Chemistry at the University Joseph Fourier in Grenoble, France in 1993. After a post-doctoral fellowship spent on the crystallization of protein, Dr. Tamagnan completed a second postdoctoral fellowship at RBI in Boston, Massachusetts, where his research focused on developing new ligands for the diagnosis of Parkinson disease using compounds labeled with radioactive atoms. Prior to joining MNI in 2001, he worked on the development of new radioligands to study neurodegenerative diseases in the NeuroImaging program at Yale University. He joined IND as Laboratory Research and Development Director in 2003.
Dr. Tamagnan has been the recipient of numerous grants and is the co-inventor of ligands used for the diagnosis of Parkinson disease.
Dr. Orcutt is Invicro’s VP of Research Services. She holds a Ph.D. in Chemical Engineering from MIT and has expertise in physical chemistry, pharmacokinetic modeling, radiochemistry, and preclinical imaging research across multiple imaging modalities (PET/SPECT/CT). Dr. Orcutt is responsible for Invicro’s contract research program. She manages the contract research team and the design, execution, analysis, and interpretation of single- and multi-site preclinical imaging studies and first-in-human studies of novel radiolabeled biologics. She also manages the integration of modeling & simulation of in vivo pharmacokinetics with preclinical imaging to better understand mechanisms of drug PK, distribution, targeting and efficacy and to guide translational efforts. Dr. Orcutt holds a B.S. from Johns Hopkins University. She completed her graduate work at MIT in Dane Wittrup’s lab, where she used a combination of protein engineering and mathematical modeling approaches to engineer a novel radioimmunotherapy approach to treating cancer. Following her graduate work, she worked as a postdoctoral fellow at Harvard Medical School in the Center for Molecular Imaging to develop cancer therapeutic and imaging agents.
Jack Mariotti is a Certified Public Accountant and holds a Bachelor Degree in Economics from the University of Michigan.
Mr. Mariotti was previously the CFO for the National Foundation for Teaching Entrepreneurship (NFTE) in New York City. He also worked as an auditor for Arthur Young, and in financial management positions at Merrill Lynch Realty and Prudential Home Mortgage.